• 1. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 2. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Phenylpiperazines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Phenylpiperazines

Methyl 4-piperazin-1-ylbenzoate (CAS No. 163210-97-7): A Comprehensive Overview in Modern Chemical and Pharmaceutical Research

Methyl 4-piperazin-1-ylbenzoate, identified by its Chemical Abstracts Service number CAS No. 163210-97-7, is a significant compound in the realm of chemical and pharmaceutical research. This molecule, characterized by its structural motif of a benzoate ester linked to a piperazine ring, has garnered attention due to its versatile applications in drug discovery and molecular pharmacology.

The compound's structure, featuring a piperazin-1-yl substituent on a benzoic acid derivative, imparts unique physicochemical properties that make it valuable in the synthesis of pharmacologically active agents. The piperazine moiety is particularly noteworthy, as it is a common pharmacophore in medicinal chemistry, known for its ability to enhance binding affinity and selectivity in biological targets.

In recent years, the investigation of methyl 4-piperazin-1-ylbenzoate has been extended to explore its potential in addressing various therapeutic challenges. One of the most compelling areas of research involves its application as a precursor in the development of novel antimicrobial agents. The combination of the benzoate group and the piperazine ring provides a scaffold that can be modified to interact with bacterial enzymes and cellular processes, offering a promising route to combat resistant strains.

Furthermore, the compound has shown promise in the field of central nervous system (CNS) drug development. The piperazine ring's ability to cross the blood-brain barrier makes it an attractive component for designing neuroactive molecules. Current studies are focusing on its derivatives as potential candidates for treating neurological disorders such as epilepsy and depression. The benzoate moiety contributes to the lipophilicity of the molecule, which is crucial for effective CNS penetration.

The synthesis of methyl 4-piperazin-1-ylbenzoate involves well-established organic chemistry techniques, including esterification and nucleophilic substitution reactions. Advanced synthetic methodologies have been employed to optimize yield and purity, ensuring that the compound meets the stringent requirements for pharmaceutical applications. These methods often incorporate green chemistry principles, reducing waste and enhancing sustainability in the production process.

From a computational chemistry perspective, methyl 4-piperazin-1-ylbenzoate has been extensively studied using molecular modeling techniques. These studies aim to elucidate its interaction with biological targets at an atomic level, providing insights into its mechanism of action. The use of high-throughput virtual screening has accelerated the identification of potential drug candidates derived from this scaffold, significantly reducing the time and cost associated with traditional screening methods.

The pharmacokinetic properties of methyl 4-piperazin-1-ylbenzoate have also been thoroughly investigated. Its metabolic stability and excretion pathways are critical factors in determining its suitability for therapeutic use. Advanced analytical techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy have been employed to characterize its degradation products and metabolic intermediates, providing valuable data for optimizing drug formulations.

In conclusion, methyl 4-piperazin-1-ylbenzoate (CAS No. 163210-97-7) represents a fascinating compound with diverse applications in modern chemical and pharmaceutical research. Its unique structural features make it a valuable tool for developing novel therapeutic agents targeting various diseases. As research continues to uncover new applications and refine synthetic methodologies, this compound is poised to play an increasingly important role in advancing medical science.

• 202262-40-6(Benzoicacid, 3-(1-piperazinyl)-, ethyl ester)
• 892502-26-0(Ethyl 4-(4-Methylperhydro-1,4-diazepin-1-yl)benzoate)
• 80518-57-6(1-(4-Ethoxycarbonylphenyl)piperazine)
• 91563-80-3(Methyl 4-(diethylamino)benzoate)
• 354813-14-2(Methyl 4-(4-methylpiperazin-1-yl)benzoate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)